Physician profile
Eamon K Dutta
NPI 1396822979
$15,333.15
in general payments reported to CMS, 2019-2025
32 companies · $2,582 in 2025
The $2,582 reported for 2025 was more than what 91% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,950 · 2020: $658 · 2021: $1,875 · 2022: $2,407 · 2023: $2,723 · 2024: $3,139 · 2025: $2,582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,444.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,443.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,956.57 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Abbvie INC. | $1,900.82 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,435.66 | 2020-2025 | Caplyta |
| Alkermes, INC. | $1,295.65 | 2019-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $1,253.33 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $1,102.87 | 2019-2025 | Ingrezza |
| Lundbeck LLC | $1,057.90 | 2019-2025 | Rexulti, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $957.30 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $910.27 | 2019-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $552.82 | 2020-2025 | Fanapt |
| Corium, LLC | $494.81 | 2021-2025 | Azstarys |
| Axsome Therapeutics, INC. | $418.84 | 2023-2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $415.15 | 2019-2022 | |
| Allergan, INC. | $191.40 | 2019-2020 | |
| Indivior INC. | $184.61 | 2020-2025 | Perseris, Sublocade |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $170.20 | 2025 | Vns Therapy Symmetry Model 8103 Generator |
| Supernus Pharmaceuticals, INC. | $168.33 | 2023-2025 | Qelbree, Qelbree |
| Noven Therapeutics, LLC | $128.59 | 2021-2025 | Secuado, Xelstrym |
| Shire North American Group INC | $126.25 | 2019 | |
| Eisai INC. | $114.92 | 2024 | |
| Ironshore Pharmaceuticals INC. | $97.47 | 2019 | |
| Idorsia Pharmaceuticals US INC | $82.54 | 2022-2024 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $78.04 | 2024-2025 | Cobenfy |
| Neos Therapeutics, LP | $47.92 | 2023-2024 | Adzenys Xr-Odt |
| Tris Pharma INC | $32.81 | 2023-2024 | Dyanavel Xr |
| Biogen, INC. | $27.81 | 2023 | |
| Acadia Pharmaceuticals INC | $25.48 | 2025 | Nuplazid |
| Almatica Pharma LLC | $24.83 | 2024 | Loreev Xr |
| Bioxcel Therapeutics, INC. | $23.56 | 2023 | Igalmi |
| Masimo Corporation | $23.03 | 2023 | Bridge |
| Lilly USA, LLC | $20.21 | 2025 | Zepbound |
| Arbor Pharmaceuticals, INC. | $13.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eamon Dutta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.